Here, we sought to answer the question regarding trends of axillary surgery in patients with pT0–2 ER+/HER2− breast cancers who received adjuvant chemotherapy, endocrine therapy, and radiation, and whether the type of axillary surgery performed had an impact on OS in this patient population. This evidence concerns the gene ESR1 and breast carcinoma.